# GLAUKOS Corp: overview

GKOS · NYSE · CIK 1192448 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/gkos.md) · [Financials](/companies/gkos/financials.md) · [Filings](/companies/gkos/filings.md) · [Insiders](/companies/gkos/insiders.md)

Latest reported revenue: [$211.0m](/filings/0001193125-26-436400.md) for Q3 FY2026, three months to 2026-09-30, from the 10-Q filed Oct 28, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-436400).

## Last eight quarters

| Line item | Unit | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [105 d](/filings/0001193125-26-061944.md) | [107](/filings/0001193125-26-193004.md) | [124](/filings/0001193125-26-324201.md) | [134](/filings/0001193125-26-436400.md) | [143 d](/filings/0001193125-26-061944.md) | [151](/filings/0001193125-26-193004.md) | [186](/filings/0001193125-26-324201.md) | [211](/filings/0001193125-26-436400.md) |
| Gross margin | % | [72.9% d](/filings/0001193125-26-061944.md) | [77.2%](/filings/0001193125-26-193004.md) | [78.3%](/filings/0001193125-26-324201.md) | [78.4%](/filings/0001193125-26-436400.md) | [(1.1%) d](/filings/0001193125-26-061944.md) | [77.9%](/filings/0001193125-26-193004.md) | [81.7%](/filings/0001193125-26-324201.md) | [85.2%](/filings/0001193125-26-436400.md) |
| Operating margin | % | [(27.2%) d](/filings/0001193125-26-061944.md) | [(19.4%)](/filings/0001193125-26-193004.md) | [(18.3%)](/filings/0001193125-26-324201.md) | [(12.3%)](/filings/0001193125-26-436400.md) | [(97.7%) d](/filings/0001193125-26-061944.md) | [(13.2%)](/filings/0001193125-26-193004.md) | [(9.3%)](/filings/0001193125-26-324201.md) | [0.4%](/filings/0001193125-26-436400.md) |
| Net margin | % | [(31.8%) d](/filings/0001193125-26-061944.md) | [(17.0%)](/filings/0001193125-26-193004.md) | [(15.8%)](/filings/0001193125-26-324201.md) | [(12.2%)](/filings/0001193125-26-436400.md) | [(93.4%) d](/filings/0001193125-26-061944.md) | [(13.1%)](/filings/0001193125-26-193004.md) | [(9.9%)](/filings/0001193125-26-324201.md) | [1.0%](/filings/0001193125-26-436400.md) |
| Diluted EPS | $ per share | not reported | [(0.32)](/filings/0001193125-26-193004.md) | [(0.34)](/filings/0001193125-26-324201.md) | [(0.28)](/filings/0001193125-26-436400.md) | not reported | [(0.34)](/filings/0001193125-26-193004.md) | [(0.31)](/filings/0001193125-26-324201.md) | [0.03](/filings/0001193125-26-436400.md) |
| Free cash flow | $m | [(1.2) d](/filings/0001193125-26-061944.md) | [(20.5)](/filings/0001193125-26-193004.md) | [5.8 d](/filings/0001193125-26-324201.md) | [(11.7) d](/filings/0001193125-26-436400.md) | [3.9 d](/filings/0001193125-26-061944.md) | [(16.5)](/filings/0001193125-26-193004.md) | [12.1 d](/filings/0001193125-26-324201.md) | [36.5 d](/filings/0001193125-26-436400.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [294](/filings/0001558370-24-001630.md) | [283](/filings/0001558370-25-001402.md) | [315](/filings/0001193125-26-061944.md) | [383](/filings/0001193125-26-061944.md) | [507](/filings/0001193125-26-061944.md) |
| Gross margin | % | [77.3%](/filings/0001558370-24-001630.md) | [75.6%](/filings/0001558370-25-001402.md) | [76.0%](/filings/0001193125-26-061944.md) | [75.5%](/filings/0001193125-26-061944.md) | [55.7%](/filings/0001193125-26-061944.md) |
| Operating margin | % | [(11.2%)](/filings/0001558370-24-001630.md) | [(29.1%)](/filings/0001558370-25-001402.md) | [(40.9%)](/filings/0001193125-26-061944.md) | [(31.9%)](/filings/0001193125-26-061944.md) | [(39.3%)](/filings/0001193125-26-061944.md) |
| Net margin | % | [(16.9%)](/filings/0001558370-24-001630.md) | [(35.1%)](/filings/0001558370-25-001402.md) | [(42.8%)](/filings/0001193125-26-061944.md) | [(38.2%)](/filings/0001193125-26-061944.md) | [(37.0%)](/filings/0001193125-26-061944.md) |
| Diluted EPS | $ per share | [(1.07)](/filings/0001558370-24-001630.md) | [(2.09)](/filings/0001558370-25-001402.md) | [(2.78)](/filings/0001193125-26-061944.md) | [(2.77)](/filings/0001193125-26-061944.md) | [(3.28)](/filings/0001193125-26-061944.md) |
| Free cash flow | $m | [(23.1)](/filings/0001558370-24-001630.md) | [(63.3)](/filings/0001558370-25-001402.md) | [(78.0)](/filings/0001193125-26-061944.md) | [(67.6)](/filings/0001193125-26-061944.md) | [(22.5)](/filings/0001193125-26-061944.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/gkos/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $1.33bn | 9,540,056 |  | Added +450,027 |
| [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $679.6m | 4,862,894 |  | Not compared |
| [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $575.8m | 5,348,395 |  | Not compared |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $464.3m | 3,321,839 |  | Added +113,476 |
| [PRIMECAP MANAGEMENT CO/CA/](/funds/763212.md) | 2026-06-30 | $425.0m | 3,040,705 |  | Reduced −329,923 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $356.5m | 2,551,132 |  | Added +42,361 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $323.7m | 2,315,568 |  | Added +132,951 |
| [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $221.0m | 1,581,016 |  | Added +407,320 |
| [Holocene Advisors, LP](/funds/1700574.md) | 2026-06-30 | $211.7m | 1,514,931 |  | Added +131,216 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $204.6m | 1,463,448 |  | Added +106,995 |

## Recent filings

[All 1,060 filings](/companies/gkos/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-28 | 17:22 ET | [10-Q](/filings/0001193125-26-436400.md) | Quarterly report, period 2026-09-30 | 0001193125-26-436400 |
| 2026-10-28 | 16:10 ET | [8-K](/filings/0001193125-26-436147.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-436147 |
| 2026-08-03 | 07:00 ET | [8-K](/filings/0001192448-26-000002.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001192448-26-000002 |
| 2026-07-29 | 17:06 ET | [10-Q](/filings/0001193125-26-324201.md) | Quarterly report, period 2026-06-30 | 0001193125-26-324201 |
| 2026-07-29 | 16:10 ET | [8-K](/filings/0001193125-26-323729.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-323729 |
| 2026-06-03 | 17:12 ET | [8-K](/filings/0001193125-26-255758.md) | 5.07 Shareholder vote results | 0001193125-26-255758 |
| 2026-05-04 | 07:00 ET | [8-K](/filings/0001193125-26-202466.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-202466 |
| 2026-04-30 | 19:30 ET | [10-Q](/filings/0001193125-26-193004.md) | Quarterly report, period 2026-03-31 | 0001193125-26-193004 |
| 2026-04-29 | 16:10 ET | [8-K](/filings/0001193125-26-191553.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-191553 |
| 2026-04-16 | 06:01 ET | [DEF 14A](/filings/0001193125-26-157829.md) | Proxy statement, period 2026-05-28 | 0001193125-26-157829 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-061944.md), filed Feb 23, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, has been scored from the reported figures. [See the target](/leagues/2026q3/targets/dcde8a9d-ab4b-4cde-8064-5e6d0237902d)

## About the filer

- CIK: 1192448
- Tickers: GKOS
- Exchange: NYSE
- SIC code: 3841 Surgical & Medical Instruments & Apparatus
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 13:05 ET. No prices; not investment advice.